LC-MS/MS profiling and analysis of Bacillus licheniformis extracellular proteins for antifungal potential against Candida albicans
Journal of Proteomics · 2024
DOI: 10.1016/j.jprot.2024.105228 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Proteomics, 2024. Verfasst von Jyoti Sankar Prusty und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, National Institute of Technology, Raipur 492010, CG, India. Hauptthemen laut MEDLINE: Candida albicans, Antifungal Agents, Bacillus licheniformis, Bacterial Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 95 Literaturangaben. Gefördert von: Ministry of Education, National Institute of Technology, Raipur.
Abstract (Originalsprache)
Candida albicans, a significant human pathogenic fungus, employs hydrolytic proteases for host invasion. Conventional antifungal agents are reported with resistance issues from around the world. This study investigates the role of Bacillus licheniformis extracellular proteins (ECP) as effective antifungal peptides (AFPs). The aim was to identify and characterize the ECP of B. licheniformis through LC-MS/MS and bioinformatics analysis. LC-MS/MS analysis identified 326 proteins with 69 putative ECP, further analyzed in silico. Of these, 21 peptides exhibited antifungal properties revealed by classAMP tool and are predominantly anionic. Peptide-protein docking revealed interactions between AFPs like Peptide chain release factor 1 (Q65DV1_Seq1: SASEQLSDAK) and Putative carboxy peptidase (Q65IF0_Seq7: SDSSLEDQDFILESK) with C. albicans virulent SAP5 proteins (PDB ID 2QZX), forming hydrogen bonds and significant Pi-Pi interactions. The identification of B. licheniformis ECP is the novelty of the study that sheds light on their antifungal potential. The identified AFPs, particularly those interacting with bonafide pharmaceutical targets SAP5 of C. albicans represent promising avenues for the development of antifungal treatments with AFPs that could be the pursuit of a novel therapeutic strategy against C. albicans. SIGNIFICANCE OF STUDY: The purpose of this work was to carry out proteomic profiling of the secretome of B. licheniformis. Previously, the efficacy of Bacillus licheniformis extracellular proteins against Candida albicans was investigated and documented in a recently communicated manuscript, showcasing the antifungal activity of these proteins. In order to achieve high-throughput identification of ES (Excretory-secretory) proteins, the utilization of liquid chromatography tandem mass spectrometry (LC-MS) was utilized. There was a lack of comprehensive research on AFPs in B. licheniformis, nevertheless. The proteins secreted by B. licheniformis in liquid medium were initially discovered using liquid chromatography-tandem mass spectrometry (LC-MS) analysis and identification in order to immediately characterize the unidentified active metabolites in fermentation broth.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology, National Institute of Technology, Raipur 492010, CG, India.
- Department of Biotechnology, National Institute of Technology, Raipur 492010, CG, India. Electronic address: awanik.bt@nitrr.ac.in.
Förderung
- Ministry of Education
- National Institute of Technology, Raipur
Zitieren
APA
Prusty, J. S., & Kumar, A. (2024). LC-MS/MS profiling and analysis of Bacillus licheniformis extracellular proteins for antifungal potential against Candida albicans. Journal of Proteomics. https://doi.org/10.1016/j.jprot.2024.105228
Vancouver
Prusty JS, Kumar A. LC-MS/MS profiling and analysis of Bacillus licheniformis extracellular proteins for antifungal potential against Candida albicans. Journal of Proteomics. 2024. doi:10.1016/j.jprot.2024.105228
BibTeX
@article{Prusty2024,
author = {Prusty, Jyoti Sankar and Kumar, Awanish},
title = {LC-MS/MS profiling and analysis of Bacillus licheniformis extracellular proteins for antifungal potential against Candida albicans},
journal = {Journal of Proteomics},
year = {2024},
doi = {10.1016/j.jprot.2024.105228}
}
EUVIMED